VERAXA Biotech (NASDAQ: VRXA) announced a collaboration with AI-driven bioinformatics company Ardigen S.A. to support development of its BiTAC(R) pipeline of T-cell engagers and future antibody-drug conjugates. The partnership will initially focus on developing AI-enabled tools to identify and prioritize synergistic dual-target combinations for VERAXA's BiTAC platform, which is designed to improve tumor targeting while reducing off-target toxicity.
VERAXA said integrating artificial intelligence into its research and development strategy could enhance target selection by analyzing large preclinical and clinical datasets, including programs that demonstrated efficacy but failed because of toxicity. The company believes the collaboration will strengthen development of precision oncology therapies and improve long-term drug development success rates. This approach addresses a critical bottleneck in oncology: many promising therapies fail due to toxicity issues that could be mitigated with better target selection.
The partnership underscores the growing role of AI in drug discovery, particularly in identifying optimal bispecific antibody combinations. VERAXA's BiTAC platform aims to engage T cells more precisely against tumors while sparing healthy tissue. By leveraging Ardigen's computational expertise, VERAXA hopes to accelerate the identification of dual-target pairs that maximize efficacy and minimize side effects. The companies will also explore AI applications for future antibody-drug conjugates, expanding the potential impact of the collaboration.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, VERAXA is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond.
For more information on the collaboration, visit https://ibn.fm/GLFg2. To stay updated on VERAXA's latest news, refer to the company's newsroom at https://ibn.fm/VRXA.
